Cargando…

Eosinophil and lymphocyte counts predict bevacizumab response and survival in recurrent glioblastoma

BACKGROUND: There is a lack of biomarkers to identify glioblastoma (GBM) patients who may benefit from specific salvage therapies, such as the anti-angiogenic agent bevacizumab. We hypothesized that circulating blood counts may serve as biomarkers for treatment response and clinical outcomes. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vaios, Eugene J, Winter, Sebastian F, Muzikansky, Alona, Nahed, Brian V, Dietrich, Jorg
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Clinical Investigations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212859/ https://www.ncbi.nlm.nih.gov/pubmed/32642690 http://dx.doi.org/10.1093/noajnl/vdaa031

Ejemplares similares

Vascular dysfunction promotes regional hypoxia after bevacizumab therapy in recurrent glioblastoma patients
por: Gerstner, Elizabeth R, et al.
Publicado: (2020)

Role of Eosinophil Relative Count and Neutrophil-to-Lymphocyte Ratio in the Assessment of Severity of Atopic Dermatitis
por: INOKUCHI-SAKATA, Sanae, et al.
Publicado: (2021)

Phase II trial of ponatinib in patients with bevacizumab‐refractory glioblastoma
por: Lee, Eudocia Q., et al.
Publicado: (2019)

Bevacizumab in recurrent glioblastoma
por: Martinez, Nina L., et al.
Publicado: (2019)

A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE)
por: Cloughesy, Timothy F, et al.
Publicado: (2020)

Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4(+) T-lymphocyte counts
por: Bota, Daniela A, et al.
Publicado: (2018)

Value of [(18)F]-FDG positron emission tomography in patients with recurrent glioblastoma receiving bevacizumab
por: Graham, Maya S, et al.
Publicado: (2020)

The impact of different volumetric thresholds to determine progressive disease in patients with recurrent glioblastoma treated with bevacizumab
por: Gahrmann, Renske, et al.
Publicado: (2022)

Defining Treatment‐Related Adverse Effects in Patients with Glioma: Distinctive Features of Pseudoprogression and Treatment‐Induced Necrosis
por: Winter, Sebastian F., et al.
Publicado: (2020)

Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data
por: Bota, Daniela A, et al.
Publicado: (2021)

Bevacizumab for the Treatment of Recurrent Glioblastoma
por: Chamberlain, Marc C.
Publicado: (2011)

Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance)
por: Galanis, Evanthia, et al.
Publicado: (2022)

Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial
por: Reardon, David A., et al.
Publicado: (2020)

Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors
por: You, Weir-Chiang, et al.
Publicado: (2023)

Days gained response discriminates treatment response in patients with recurrent glioblastoma receiving bevacizumab-based therapies
por: Singleton, Kyle W, et al.
Publicado: (2020)

Bevacizumab for Patients with Recurrent Multifocal Glioblastomas
por: Burger, Michael C., et al.
Publicado: (2017)

Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma
por: Bertaut, Aurélie, et al.
Publicado: (2016)

Peripheral eosinophil count and eosinophil-to-lymphocyte ratio are associated with revision sinus surgery
por: Bayer, Karina, et al.
Publicado: (2022)

Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma
por: Ellingson, Benjamin M, et al.
Publicado: (2021)

Bevacizumab combined with re-irradiation in recurrent glioblastoma
por: She, Lei, et al.
Publicado: (2022)

Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients
por: Reardon, D A, et al.
Publicado: (2012)

Bevacizumab Improves Quality of Life in Patients with Recurrent Glioblastoma
por: Nagpal, Seema, et al.
Publicado: (2011)

Safety and efficacy of bevacizumab biosimilar in recurrent/ progressive glioblastoma
por: Kumar, Gunjesh, et al.
Publicado: (2021)

Actinomycin D downregulates Sox2 and improves survival in preclinical models of recurrent glioblastoma
por: Taylor, Jessica T, et al.
Publicado: (2020)

Machine-Learning-Based Radiomics MRI Model for Survival Prediction of Recurrent Glioblastomas Treated with Bevacizumab
por: Ammari, Samy, et al.
Publicado: (2021)

Efficacy and safety of bevacizumab in Turkish patients with metastatic and recurrent cervical cancer
por: Ercelep, Özlem, et al.
Publicado: (2020)

Eosinophil count and neutrophil-to-lymphocyte count ratio as biomarkers for predicting early-onset neonatal sepsis
por: Lee, Jang Hoon
Publicado: (2019)

Increased epithelial membrane protein 2 expression in glioblastoma after treatment with bevacizumab
por: Patel, Kunal S, et al.
Publicado: (2020)

Bevacizumab for glioblastoma
por: Narita, Yoshitaka
Publicado: (2015)

The Correlation of Neutrophil–Lymphocyte Ratio and Eosinophil Count with SCORTEN in SJS/TEN
por: Primisawitri, Pratiwi Prasetya, et al.
Publicado: (2022)

MR spectroscopic imaging predicts early response to anti-angiogenic therapy in recurrent glioblastoma
por: Talati, Pratik, et al.
Publicado: (2021)

Bevacizumab-based treatment as salvage therapy in patients with recurrent symptomatic brain metastases
por: Berghoff, Anna Sophie, et al.
Publicado: (2020)

A multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma
por: Kumthekar, Priya, et al.
Publicado: (2022)

Expansion of effector and memory T cells is associated with increased survival in recurrent glioblastomas treated with dendritic cell immunotherapy
por: Eoli, Marica, et al.
Publicado: (2019)

Change in volumetric tumor growth rate after cytotoxic therapy is predictive of overall survival in recurrent glioblastoma
por: Oshima, Sonoko, et al.
Publicado: (2023)

High VEGFA Expression Is Associated with Improved Progression-Free Survival after Bevacizumab Treatment in Recurrent Glioblastoma
por: Alves, Bárbara, et al.
Publicado: (2023)

Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice
por: de Groot, John F., et al.
Publicado: (2010)

Whole-Genome Multi-omic Study of Survival in Patients with Glioblastoma Multiforme
por: Bernal Rubio, Yeni L., et al.
Publicado: (2018)

Analysis of Changes in the Total Lymphocyte and Eosinophil Count during Immunotherapy for Metastatic Renal Cell Carcinoma: Correlation with Response and Survival
por: Jeong, In Gab, et al.
Publicado: (2007)

VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance
por: Michaelsen, Signe R, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6uhe0ajpsvocl1unhjnr12ee15